Biomark Diagnostics Stock Number Of Shares Shorted
| BMKDF Stock | USD 0.14 0.02 16.67% |
BioMark Diagnostics fundamentals help investors to digest information that contributes to BioMark Diagnostics' financial success or failures. It also enables traders to predict the movement of BioMark Pink Sheet. The fundamental analysis module provides a way to measure BioMark Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioMark Diagnostics pink sheet.
BioMark |
BioMark Diagnostics Company Number Of Shares Shorted Analysis
BioMark Diagnostics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, BioMark Diagnostics has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Diagnostics & Research industry. The number of shares shorted for all United States stocks is 100.0% higher than that of the company.
BioMark Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioMark Diagnostics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioMark Diagnostics could also be used in its relative valuation, which is a method of valuing BioMark Diagnostics by comparing valuation metrics of similar companies.BioMark Diagnostics is currently under evaluation in number of shares shorted category among its peers.
BioMark Fundamentals
| Return On Asset | -1.45 | |||
| Operating Margin | (15.72) % | |||
| Current Valuation | 12.8 M | |||
| Shares Outstanding | 83.29 M | |||
| Shares Owned By Insiders | 54.77 % | |||
| Price To Earning | (8.80) X | |||
| Price To Sales | 105.81 X | |||
| Revenue | 43.93 K | |||
| Gross Profit | 43.93 K | |||
| EBITDA | (1.22 M) | |||
| Net Income | (1.45 M) | |||
| Cash And Equivalents | 364.96 K | |||
| Total Debt | 96.3 K | |||
| Current Ratio | 0.35 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (1.2 M) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 0.66 | |||
| Market Capitalization | 11.74 M | |||
| Total Asset | 1.47 M | |||
| Retained Earnings | (3.47 M) | |||
| Working Capital | (461 K) | |||
| Current Asset | 19 K | |||
| Current Liabilities | 480 K | |||
| Z Score | 69.8 | |||
| Net Asset | 1.47 M |
About BioMark Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioMark Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioMark Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioMark Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in BioMark Pink Sheet
BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.